vs

Side-by-side financial comparison of 1stdibs.com, Inc. (DIBS) and Avidity Biosciences, Inc. (RNA). Click either name above to swap in a different company.

1stdibs.com, Inc. is the larger business by last-quarter revenue ($23.0M vs $12.5M, roughly 1.8× Avidity Biosciences, Inc.). 1stdibs.com, Inc. runs the higher net margin — -4.5% vs -1398.3%, a 1393.8% gap on every dollar of revenue. On growth, Avidity Biosciences, Inc. posted the faster year-over-year revenue change (434.0% vs 0.9%). 1stdibs.com, Inc. produced more free cash flow last quarter ($3.6M vs $-156.9M). Over the past eight quarters, Avidity Biosciences, Inc.'s revenue compounded faster (138.5% CAGR vs 2.0%).

1stdibs.com, Inc. is an American e-commerce company. It has an online marketplace, which sells luxury items such as high-end furniture for interior design, fine art and jewelry. The company has been recognized for "pushing the antiques business into the 21st century." Originally, founded in Paris, it is headquartered in New York City.

Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named.

DIBS vs RNA — Head-to-Head

Bigger by revenue
DIBS
DIBS
1.8× larger
DIBS
$23.0M
$12.5M
RNA
Growing faster (revenue YoY)
RNA
RNA
+433.2% gap
RNA
434.0%
0.9%
DIBS
Higher net margin
DIBS
DIBS
1393.8% more per $
DIBS
-4.5%
-1398.3%
RNA
More free cash flow
DIBS
DIBS
$160.5M more FCF
DIBS
$3.6M
$-156.9M
RNA
Faster 2-yr revenue CAGR
RNA
RNA
Annualised
RNA
138.5%
2.0%
DIBS

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
DIBS
DIBS
RNA
RNA
Revenue
$23.0M
$12.5M
Net Profit
$-1.0M
$-174.4M
Gross Margin
73.5%
Operating Margin
-10.1%
-1513.5%
Net Margin
-4.5%
-1398.3%
Revenue YoY
0.9%
434.0%
Net Profit YoY
80.0%
-117.0%
EPS (diluted)
$-0.02
$-1.27

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
DIBS
DIBS
RNA
RNA
Q4 25
$23.0M
Q3 25
$22.0M
$12.5M
Q2 25
$22.1M
$3.8M
Q1 25
$22.5M
$1.6M
Q4 24
$22.8M
$3.0M
Q3 24
$21.2M
$2.3M
Q2 24
$22.2M
$2.0M
Q1 24
$22.1M
$3.5M
Net Profit
DIBS
DIBS
RNA
RNA
Q4 25
$-1.0M
Q3 25
$-3.5M
$-174.4M
Q2 25
$-4.3M
$-157.3M
Q1 25
$-4.8M
$-115.8M
Q4 24
$-5.2M
$-102.3M
Q3 24
$-5.7M
$-80.4M
Q2 24
$-4.4M
$-70.8M
Q1 24
$-3.3M
$-68.9M
Gross Margin
DIBS
DIBS
RNA
RNA
Q4 25
73.5%
Q3 25
74.3%
Q2 25
71.8%
Q1 25
72.4%
Q4 24
72.3%
Q3 24
71.0%
Q2 24
71.7%
Q1 24
72.5%
Operating Margin
DIBS
DIBS
RNA
RNA
Q4 25
-10.1%
Q3 25
-21.3%
-1513.5%
Q2 25
-25.8%
-4448.7%
Q1 25
-27.7%
-8360.9%
Q4 24
-30.6%
-4069.6%
Q3 24
-34.9%
-4200.9%
Q2 24
-29.2%
-4040.4%
Q1 24
-24.3%
-2178.6%
Net Margin
DIBS
DIBS
RNA
RNA
Q4 25
-4.5%
Q3 25
-16.0%
-1398.3%
Q2 25
-19.5%
-4089.3%
Q1 25
-21.3%
-7360.0%
Q4 24
-22.9%
-3439.5%
Q3 24
-26.8%
-3441.7%
Q2 24
-20.0%
-3461.8%
Q1 24
-15.0%
-1943.4%
EPS (diluted)
DIBS
DIBS
RNA
RNA
Q4 25
$-0.02
Q3 25
$-0.10
$-1.27
Q2 25
$-0.12
$-1.21
Q1 25
$-0.14
$-0.90
Q4 24
$-0.14
$-0.80
Q3 24
$-0.15
$-0.65
Q2 24
$-0.12
$-0.65
Q1 24
$-0.08
$-0.79

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
DIBS
DIBS
RNA
RNA
Cash + ST InvestmentsLiquidity on hand
$22.9M
$350.2M
Total DebtLower is stronger
Stockholders' EquityBook value
$93.6M
$1.9B
Total Assets
$132.1M
$2.1B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
DIBS
DIBS
RNA
RNA
Q4 25
$22.9M
Q3 25
$19.9M
$350.2M
Q2 25
$22.4M
$243.9M
Q1 25
$20.3M
$254.2M
Q4 24
$26.0M
$219.9M
Q3 24
$22.0M
$370.2M
Q2 24
$23.8M
$575.8M
Q1 24
$33.7M
$471.4M
Stockholders' Equity
DIBS
DIBS
RNA
RNA
Q4 25
$93.6M
Q3 25
$94.0M
$1.9B
Q2 25
$94.9M
$1.2B
Q1 25
$96.2M
$1.3B
Q4 24
$99.3M
$1.4B
Q3 24
$107.2M
$1.5B
Q2 24
$110.4M
$1.2B
Q1 24
$131.0M
$830.9M
Total Assets
DIBS
DIBS
RNA
RNA
Q4 25
$132.1M
Q3 25
$135.2M
$2.1B
Q2 25
$138.6M
$1.4B
Q1 25
$142.5M
$1.5B
Q4 24
$145.8M
$1.6B
Q3 24
$154.4M
$1.6B
Q2 24
$157.6M
$1.3B
Q1 24
$179.5M
$951.5M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
DIBS
DIBS
RNA
RNA
Operating Cash FlowLast quarter
$4.3M
$-156.2M
Free Cash FlowOCF − Capex
$3.6M
$-156.9M
FCF MarginFCF / Revenue
15.7%
-1257.6%
Capex IntensityCapex / Revenue
2.9%
5.7%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-3.2M
$-592.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
DIBS
DIBS
RNA
RNA
Q4 25
$4.3M
Q3 25
$-1.5M
$-156.2M
Q2 25
$-5.1M
$-199.7M
Q1 25
$-96.0K
$-124.8M
Q4 24
$2.8M
$-99.9M
Q3 24
$-3.0K
$-65.6M
Q2 24
$-2.6M
$-65.0M
Q1 24
$-3.1M
$-70.4M
Free Cash Flow
DIBS
DIBS
RNA
RNA
Q4 25
$3.6M
Q3 25
$-1.5M
$-156.9M
Q2 25
$-5.2M
$-203.0M
Q1 25
$-143.0K
$-128.6M
Q4 24
$1.5M
$-103.8M
Q3 24
$-44.0K
$-67.3M
Q2 24
$-3.0M
$-65.5M
Q1 24
$-3.3M
$-71.3M
FCF Margin
DIBS
DIBS
RNA
RNA
Q4 25
15.7%
Q3 25
-6.8%
-1257.6%
Q2 25
-23.4%
-5277.1%
Q1 25
-0.6%
-8174.3%
Q4 24
6.5%
-3491.0%
Q3 24
-0.2%
-2881.8%
Q2 24
-13.5%
-3204.6%
Q1 24
-14.8%
-2012.3%
Capex Intensity
DIBS
DIBS
RNA
RNA
Q4 25
2.9%
Q3 25
0.1%
5.7%
Q2 25
0.2%
86.9%
Q1 25
0.2%
238.6%
Q4 24
5.8%
131.7%
Q3 24
0.2%
72.9%
Q2 24
1.6%
26.0%
Q1 24
0.9%
25.8%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons